Title:
ネコ科動物の代謝異常の治療
Document Type and Number:
Japanese Patent JP6774449
Kind Code:
B2
Abstract:
The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.
More Like This:
Inventors:
Reich Dania Bart
The Hague-Diagarten Silke
Hennings Rare Janet
Cry sasukia
Trasuan M
The Hague-Diagarten Silke
Hennings Rare Janet
Cry sasukia
Trasuan M
Application Number:
JP2018023857A
Publication Date:
October 21, 2020
Filing Date:
February 14, 2018
Export Citation:
Assignee:
Boehringer Ingelheim Vetmedica GmbH
International Classes:
A61K31/351; A61K31/381; A61K38/28; A61P3/00; A61P3/10; A61P43/00
Domestic Patent References:
| JP2012517975A | ||||
| JP2009507809A | ||||
| JP6293897B2 | ||||
| JP2010522244A |
Foreign References:
| EP2368552A1 | ||||
| WO2012062698A1 | ||||
| WO2010048358A2 |
Other References:
GENERAL AND COMPARATIVE ENDOCRINOLOGY,2013年 2月 1日,Vol.182,p.48-53
Attorney, Agent or Firm:
Shinichiro Tanaka
Hiroyuki Suda
Kazuo Yamazaki
Satsuki Ichikawa
Hironobu Hattori
Toshio Takizawa
Hiroyuki Suda
Kazuo Yamazaki
Satsuki Ichikawa
Hironobu Hattori
Toshio Takizawa